Key Highlights

  • Kiniksa raised 2026 ARCALYST revenue guidance to $1,045 million to $1,050 million from $980 million to $995 million.
  • Centene lifted 2026 adjusted EPS guidance to above $5.20, an increase of $0.40.
  • Ensign Group raised its adjusted EPS range to $7.94 to $8.02 from $7.75 to $7.85.
  • IQVIA guided adjusted EPS to $12.90 to $13.00 even as it cut backlog by about $2.1 billion.
  • Repligen raised revenue guidance to $844 million to $852 million, including BioLife from October 6.

Which Healthcare Companies Raised 2026 Guidance on October 27?

Six healthcare companies raised or updated 2026 outlooks with results on Tuesday, October 27. IQVIA (NYSE:IQV) guided adjusted EPS to $12.90 to $13.00 after a $2.1 billion backlog reduction, and Centene (NYSE:CNC) lifted adjusted EPS guidance to above $5.20 after a $0.58 quarter. Repligen (NASDAQ:RGEN) raised revenue guidance to $844 million to $852 million, Ensign Group (NASDAQ:ENSG) raised adjusted EPS to $7.94 to $8.02, and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) put ARCALYST revenue at $1,045 million to $1,050 million.

ICON (NASDAQ:ICLR) updated its ranges to revenue of $8,100 million to $8,200 million and adjusted EPS of $10.35 to $10.65, even though third-quarter revenue fell 2.9%. The common thread is that most raises rested on volume, bookings or pricing rather than a single item, although Repligen's GAAP result and IQVIA's backlog cut show that headline quality varied. Each outlook is condensed below.

IQVIA: Why Raise Guidance After a $2.1 Billion Backlog Cut?

IQVIA reported adjusted EPS of $3.34, up 11.3%, against $3.28 as screened, on revenue of $4,428 million, up 8.0%. Management trimmed R&D Solutions backlog by about $2.1 billion to $32.6 billion after reviewing inactive trials, while net new bookings rose 15% to $3.2 billion, a book-to-bill ratio of 1.2.

The raised outlook includes revenue of $17,350 million to $17,500 million. Implied fourth-quarter adjusted EPS is about $3.52 to $3.62 (calculated), since no separate guide was given. Adjusted EBITDA rose 8.7% to $1,032 million and net leverage was 3.45 times, after $950 million of buybacks in nine months. The investor day is on December 1.

Centene: How Did a $0.58 Quarter Lift the 2026 Outlook?

Centene reported adjusted EPS of $0.58 against $0.50 a year earlier, with a screened estimate of $0.10, and revenue of $50,647 million. GAAP EPS was a loss of $0.14, compared with a loss of $13.50 that included a $6,723 million goodwill impairment.

Adjusted EPS guidance is now above $5.20, up from above $4.80, with revenue guided to $196.5 billion to $200.5 billion. The health benefits ratio was 92.7%, flat, and the repurchase authorization was raised by $2.0 billion. Adjusted SG&A fell to 6.5% of revenue from 7.0%, and Marketplace membership fell about 42% to roughly 3.40 million. No 2027 outlook was given.

Repligen: Does the Raised Outlook Survive a GAAP Loss?

Repligen earned adjusted EPS of $0.53 against $0.46 as screened and reported revenue of $209.3 million, ahead of the $206.7 million estimate. A $41.2 million intangible impairment pushed GAAP EPS to a loss of $0.68.

Guidance calls for adjusted EPS of $2.05 to $2.09, organic growth of 12% to 13% and an adjusted EBITDA margin near 21%. The range includes BioLife from its October 6 closing, and cash and securities stood at $863 million. Adjusted EBITDA was $43.8 million, a 20.9% margin, and organic growth was 12.5%.

Ensign Group: What Lifted Adjusted EPS to $2.03?

Ensign Group posted adjusted EPS of $2.03, up 23.8%, against $1.97 as screened, on revenue of $1,484.0 million, up 14.5%. Same-facility occupancy rose to 84.1% from 82.8%, and skilled mix reached 49.7%.

The 2026 revenue range is $5.89 billion to $5.92 billion, with the low end raised. The company added 22 operations, including its first in Florida, and held its quarterly dividend at $0.065 per share. Adjusted EBITDA rose 26.2% to $190.7 million, about 12.9% of revenue (calculated).

Kiniksa: Is ARCALYST Heading Past $1 Billion?

Kiniksa makes ARCALYST for recurrent pericarditis. Net revenue was $286.0 million, up about 58%, and GAAP EPS was $0.56 against $0.23 and a $0.31 estimate as screened.

The guidance range implies roughly $301 million to $306 million of fourth-quarter revenue (calculated), and cash was $568.8 million with no debt. About 23% of roughly 14,000 annual multiple-recurrence patients were on ARCALYST, and more than 5,450 prescribers have written prescriptions. KPL-387 Phase 3 data are expected in the second half of 2027.

ICON: Did Bookings Outweigh a 2.9% Revenue Decline?

ICON reported revenue of $2,024.8 million and adjusted EPS of $2.66, against a $2.63 estimate as screened and $3.20 a year earlier. Gross bookings rose 26.9% to $3,789 million, a book-to-bill ratio of 1.56, and backlog reached $24.5 billion.

The EPS midpoint of $10.50 is unchanged from July (calculated), but the revenue range moved up. The company repurchased $400.0 million of shares and raised its authorization to $750.0 million. Free cash flow was $302.4 million, and adjusted EBITDA was $336.9 million at a 16.6% margin.

Raised Healthcare Guidance Compared: Who Moved the Most?

On calculated midpoints, Kiniksa's ARCALYST range rose about 6.1% ($1,047.5 million versus $987.5 million), Centene's adjusted EPS floor rose about 8.3% ($5.20 versus $4.80), Ensign Group's EPS midpoint rose about 2.3% ($7.98 versus $7.80) and ICON's revenue midpoint rose about 1.9% ($8,150 million versus $8,000 million). ICON's EPS midpoint did not move, and IQVIA and Repligen releases did not state prior ranges.

Revenue growth ran from about 58% at Kiniksa and 14.5% at Ensign Group to 11% at Repligen, 8.0% at IQVIA and minus 2.9% at ICON, a calculated gap of about 60.9 points between the first and last. Against screened EPS estimates, Kiniksa's $0.25 gap was widest, and ICON's 1.25% was narrowest.

What to Watch Next: Calls, Investor Day and 2027 Readouts

ICON hosts its call at 8:00 a.m. Eastern on Wednesday, October 28, and Ensign Group at 10:00 a.m. Pacific the same day. IQVIA holds its investor day on December 1, Kiniksa expects to start a Phase 1 trial for KPL-1161 by the end of 2026, and Repligen reports fourth-quarter results in early 2027. Centene gave no dated events, and the Kiniksa balance sheet table in its release carried a June 30 label although the text refers to September 30, so cash figures follow the text.